金禾實業(002597.SZ)通過美國FDA現場檢查
格隆匯3月13日丨金禾實業(002597.SZ)公佈,公司於2020年1月13日至2020年1月14日接受了美國食品藥品監督管理局(下稱“FDA”)的CGMP現場檢查,此次檢查涉及的產品主要為公司甜味劑產品:安賽蜜和三氯蔗糖,以及香料產品:甲、乙基麥芽酚和MCP。
近日,公司收到FDA通知,按照美國21CFR法規,FDA確認此次現場檢查已結束,並出具現場檢查報告(即EIR,Establishment Inspection Report),且無FDA 483不符合項,表明公司通過了此次現場檢查,符合FDA的要求。
此次FDA現場檢查是公司首次通過FDA按照CGMP規範進行的現場檢查,標誌着公司甜味劑和香料產品的生產質量及食品安全管理已達到較高水平,有助於公司進一步開拓美國市場,對公司在全球市場的拓展帶來積極的影響,對公司未來發展有着積極的推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.